Novo Nordisk A/S
How digital health companies are capitalizing on the GLP-1 boom
Patent protection for Wegovy — Novo Nordisk’s blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and is at least twice as effective — is expected to expire by the decade’s end. Michael Siluk | UCG | Getty Images For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had […]
Read More
Eli Lilly’s big GLP-1 investment — plus, what we want from 4 portfolio stock earnings
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. Wall Street was bouncing higher Friday after, as Jim Cramer put it, a “really bad day” in the prior session. Thursday’s late-day decline happened as bond yields rose on […]
Read More
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins
A patient injects herself with an insulin pen. Guido Krzikowski | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The rivalry between Eli Lilly and Novo Nordisk extends beyond a buzzy class of weight loss and diabetes drugs called GLP-1s. […]
Read More
AstraZeneca targets $80 billion in total revenue by 2030 in ‘post-Covid era’
The Astrazeneca logo is pictured at the World Artificial Intelligence Conference 2021 in Shanghai, China, July 7, 2021. Costfoto | Future Publishing | Getty Images LONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. “We have […]
Read More
Hims & Hers Health adds compounded GLP-1 injections to weight loss program
Products of Hims & Hers displayed. Hims & Hers Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday. The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December. But GLP-1 […]
Read More
Roche says weight loss drug shows promising results in early trial
A logo at the Roche Holding AG headquarters in Basel, Switzerland, on Thursday, Feb. 1, 2024. Bloomberg | Getty Images Roche on Thursday said its experimental weight loss drug showed promising results in an early-stage trial, boosting the company’s bid to compete in the booming market for those treatments. The Swiss company joined a slate of […]
Read More
Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey says
Rebekah Carl poses with her prescription of Wegovy in New Columbia, Pennsylvania, U.S., November 13, 2023. Hannah Beier | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The use of a buzzy class of weight loss and diabetes medications is more common […]
Read More
People on Novo Nordisk’s Wegovy maintain weight loss for up to four years, study says
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Patients taking Novo Nordisk‘s obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis published Tuesday from the longest clinical trial to date […]
Read More
Shares creating the most important premarket moves: GameStop, AMC, Alibaba, Sony and additional
Check out out the firms generating the most important moves in premarket buying and selling: Meme shares — GameStop soared 120%, adding to the 74.4% it received Monday , following the person who fueled the 2021 GameStop frenzy “Roaring Kitty” posted on the internet for the initially time in about three many years. Shares of […]
Read More
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, Dec. 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! A highly popular group of weight loss and diabetes drugs is still hard […]
Read More